Oct 8, 2026 09:22AM
Oct 8, 2026 09:22AM
Sep 15, 2026 07:31AM
Sep 14, 2026 09:26AM
Sep 14, 2026 09:26AM
May 19, 2026 08:01AM
May 14, 2026 07:30AM Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Mar 19, 2026 09:25AM
Mar 9, 2026 09:15AM
Mar 9, 2026 09:15AM
Feb 17, 2026 09:15AM
Feb 17, 2026 09:15AM
Feb 11, 2026 09:16AM
Feb 11, 2026 09:15AM Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
Feb 9, 2026 09:15AM
Feb 9, 2026 09:15AM
Jan 8, 2026 08:46AM
Jan 8, 2026 08:45AM
Dec 18, 2025 08:45AM
Dec 18, 2025 08:45AM
Dec 4, 2025 09:00AM Biofrontera completes phase 1 study of Ameluz for actinic keratoses treatment
Dec 4, 2025 09:00AM
Dec 2, 2025 08:45AM
Dec 2, 2025 08:45AM
Nov 13, 2025 08:15AM
Nov 7, 2025 08:00AM
Nov 7, 2025 08:00AM
Sep 16, 2025 10:30AM Biofrontera completes enrollment in phase 3 Ameluz study for skin lesions
Sep 16, 2025 10:30AM
Sep 16, 2025 10:30AM
Aug 25, 2025 08:27AM
Aug 25, 2025 08:25AM
Aug 11, 2025 04:25PM
Aug 11, 2025 04:25PM
Jun 30, 2025 08:00AM Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
Jun 3, 2025 02:30PM
Jun 3, 2025 02:30PM
May 15, 2025 12:17PM
May 15, 2025 12:17PM
Mar 21, 2025 08:00AM
Mar 18, 2025 09:30AM
Jan 8, 2025 09:51AM Biofrontera (BFRI) Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of Superficial Basal Cell Carcinoma
Jan 8, 2025 09:50AM
Dec 23, 2024 09:31AM
Dec 23, 2024 09:30AM
Nov 13, 2024 05:15PM
Oct 31, 2024 10:33AM
Oct 31, 2024 10:32AM
Oct 14, 2024 10:30AM Biofrontera (BFRI) Announces Database Lock Of Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of sBCC
Oct 14, 2024 10:30AM

334,273 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All